drugset / Trial / NCT07204340
TLN-372 in Advanced KRAS Mutant Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid tumors
Timeline
- Start
- 2025-09-29
- Primary completion
- 2031-12-03
- Completion
- 2032-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TLN-372 | Unknown | — | — |
| Background | Cetuximab | Monoclonal antibody | — | — |
| Background | Pembrolizumab | Monoclonal antibody | — | — |
Indications
No indication recorded.